Lataa...
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy
Numerous clinical trials of mesenchymal stromal/stem cells (MSCs) as a new treatment for coronavirus-induced disease (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion. There is no approved effective therapy for COVID-19, but MSC therapies have shown first prom...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7249852/ https://ncbi.nlm.nih.gov/pubmed/32574263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01091 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|